Related Experiment Video
Updated: Jul 6, 2025
Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
Shifting the trajectory of therapeutic development for neurological and psychiatric disorders
Dimitri Krainc1, William J Martin2, Bradford Casey3
1Davee Department of Neurology, Simpson Querrey Center for Neurogenetics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Abstract:
Clinical trials for central nervous system disorders often enroll patients with unrecognized heterogeneous diseases, leading to costly trials that have high failure rates. Here, we discuss the potential of emerging technologies and datasets to elucidate disease mechanisms and identify biomarkers to improve patient stratification and monitoring of disease progression in clinical trials for neuropsychiatric disorders. Greater efforts must be centered on rigorously standardizing data collection and sharing of methods, datasets, and analytical tools across sectors. To address health care disparities in clinical trials, diversity of genetic ancestries and environmental exposures of research participants and associated biological samples must be prioritized.
Insights
Emerging technologies can improve clinical trials for neuropsychiatric disorders by enabling better patient stratification and monitoring. Standardizing data and prioritizing participant diversity are crucial for success and addressing health disparities.
Area of Science:
- Neuroscience
- Clinical Trials
- Biomarker Discovery
Background:
- Clinical trials for central nervous system disorders face challenges due to patient heterogeneity, leading to high failure rates.
- Unrecognized diseases within trial populations complicate the elucidation of disease mechanisms and progression.
Purpose of the Study:
- To discuss the potential of emerging technologies and datasets in improving clinical trials for neuropsychiatric disorders.
- To highlight the need for enhanced patient stratification, monitoring, and addressing health disparities.
Main Methods:
- Review of emerging technologies and datasets relevant to neuropsychiatric disorders.
- Discussion on the importance of data standardization and sharing.
- Emphasis on prioritizing diversity in research participants.
Main Results:
- Emerging technologies offer potential for better understanding of disease mechanisms.
- Biomarker identification can improve patient stratification and monitoring.
- Standardized data collection and sharing are essential for trial efficiency.
Conclusions:
- Integrating advanced technologies and diverse datasets can optimize clinical trials for central nervous system disorders.
- Prioritizing participant diversity is key to reducing health care disparities in research.
Related Concept Videos
01:28Preclinical Development: Overview
01:11Clinical Trials: Overview
01:28Drug Therapy
Antianxiety Medications
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:22Alzheimer's Disease: Treatment
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...